Related Experiment Video
Updated: Jul 24, 2025
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
Evaluation of FGFR Alteration Status in Urothelial Tumors
Veronika Bahlinger1, Markus Eckstein2, Arndt Hartmann2
1Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. veronika.bahlinger@uk-erlangen.de.
Abstract:
FGFR alterations in urothelial carcinoma are key driver alterations of tumorigenesis and are long recognized. In 2019 the Food and Drug Administration (FDA) approved the first pan-FGFR inhibitor, as the first specific targeted therapy in urothelial carcinoma. To receive the drug, alteration testing is required, and only alteration carriers can profit of this new agent. Due to this clinical need of detection and analysis of FGFR, here we describe two distinct and specific analytical methodologies: the SNaPshot analysis of nine FGFR3 point mutations and the QIAGEN therascreen® FGFR RGQ RT-PCR Kit, the FDA-approved companion diagnostic kit.
Insights
Fibroblast Growth Factor Receptor (FGFR) alterations drive urothelial carcinoma. Two new analytical methods, SNaPshot and QIAGEN therascreen, detect these FGFR alterations for targeted therapy eligibility.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Fibroblast Growth Factor Receptor (FGFR) alterations are recognized drivers of urothelial carcinoma.
- Targeted therapies, including the first pan-FGFR inhibitor approved by the FDA in 2019, offer new treatment avenues for urothelial carcinoma patients.
Purpose of the Study:
- To address the clinical need for detecting FGFR alterations.
- To describe two distinct and specific analytical methodologies for FGFR alteration analysis.
Main Methods:
- SNaPshot analysis for nine FGFR3 point mutations.
- Utilizing the QIAGEN therascreen FGFR RGQ RT-PCR Kit, an FDA-approved companion diagnostic kit.
Main Results:
- The study presents two validated methodologies for FGFR alteration detection.
- These methods facilitate patient identification for targeted FGFR inhibitor therapy.
Conclusions:
- Accurate detection of FGFR alterations is crucial for guiding targeted therapy in urothelial carcinoma.
- The described analytical methods provide reliable tools for clinical FGFR testing.
More Related Videos
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
07:36Quantitative Real-Time PCR Evaluation of microRNA Expressions in Mouse Kidney with Unilateral Ureteral Obstruction
Published on: August 27, 2020